Procedures for the synthesis and radioactive labeling of L-glucosylceramide are described. This compound is a stereoisomeric analogue of D-glucosylceramide which occurs in nature and accumulates in pathological quantity in the organs and tissues of patients with Gaucher disease. The properties of L-glucosylceramide that have been examined so far have been found to be indistinguishable from those of the naturally occurring glycolipid. However, L-glucosylceramide is completely refractory to enzymatic hydrolysis by purified placental glucocerebrosidase and enzyme(s) present in whole tissue extracts. It is anticipated that L-glucosylceramide will be a uniquely useful substance for exploring pathogenetic processes in animal analogues of Gaucher disease.
The pathogenesis of most lysosomal storage disorders is poorly understood at this time although clear definitions of the primary enzymatic lesions often exist (1) . Because of this situation, information relating to the pathologic manifestations of these diseases has depended primarily on descriptions of clinical courses in patients afflicted with these disorders and on the findings at postmortem examinations. The pathogenetic basis of the anatomical and physiological alterations of these disorders has been largely confined to speculation. Gaucher disease is a classic example of this dilemma. This disorder is caused by a deficiency of glucocerebroside-3-glucosidase activity in the tissues of affected individuals (2) . It has recently been shown in a patient with non-neuropathic form of the disorder (type I) that this deficiency arises from a structural mutation in the enzyme that results in markedly decreased hydrolysis of glucosylceramide without apparent effect on the affinity of the enzyme for the substrate (3) . The molecular bases that distinguish the two neuropathic forms of Gaucher diseases (types II and III) from type I Gaucher disease are not known. In addition, the pathophysiologic consequences of the accumulation of glucosylceramide are poorly understood. For example, it has been observed that there is a wide variation in the quantity of glucosylceramide in the liver of patients with Gaucher disease and that there often is little or no correlation of this accumulation with (i) the level of residual glucocerebrosidase activity or (ii) the severity of the clinical manifestations (4) .
The availability of an experimental model of Gaucher disease seems to be a paramount requirement for answering many of these puzzling questions. Although a strain of mutant BALB/c mice with hepatic and splenic accumulation of glucocerebroside has recently been reported, the clinical manifestations of the disease in these mice are not typical of Gaucher disease (5) . Investigators have attempted to inhibit glucocerebrosidase activity by the administration of conduritol-3-epoxide to induce a syndrome resembling Gaucher disease in mice (6) . However, the quantity of glucosylceramide that accumulated in liver and spleen was only 2-to 3-fold greater than that in normal mice and is therefore far below that found in patients with Gaucher disease (4) . In addition, the typical Gaucher bodies or tubular structures characteristic of the disorder were not observed in spleen, liver, or bone marrow of mice treated with this reagent (7) .
Because of the lack of a suitable Gaucher disease model at the enzyme level, investigators have attempted with little success, to produce Gaucher disease-like lesions by the administration (intraperitoneally or orally) of high levels of galactosylceramide to rats and rabbits (8) . When radioactive glucosylceramide was administered intravenously to rats, it was rapidly cleared from the plasma and taken up by the reticuloendothelial system where it was quickly catabolized, and no accumulation could be demonstrated (unpublished data). The pronounced susceptibility of glucosylceramide to normal catabolic processes pointed to the desirability of attempting to prepare a substrate analogue with the chemical and physical properties of the natural glycolipid but with the added feature of its being resistant to enzymatic hydrolysis. It was considered likely that glucosylceramide containing L-glucose instead of the naturally occurring D-glucose might be useful in this regard. 
MATERIALS AND METHODS

Materials
Silica gel 60 (E. Merck) plates were used for thin-layer chromatography. The migration of glycolipids was visualized by charring with ammonium bisulfate (9) . The silica gel used for column chromatography was Bio-Sil HA (minus 35 mesh; Bio-Rad) that was activated prior to use by heating at 1100C for 12 hr. Hydrogen bromide in acetic acid was obtained from Koch-Light Labs (Colnbrook, England). Radioactive measurements were carried out in a Searle mark III liquid scintillation system using Aquasol (New England Nuclear). 3-0-Benzoyl-N-palmitoyl-DL-sphingosine, mp 77-78, and The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact.
(Berthold) radioscanner. Melting points were taken on a Thomas-Hoover melting point apparatus and are reported corrected. Synthesis of glucocerebrosides 1,2,3,4,6-Penta-O-acetyl-,-L-glucopyranoside. A mixture of 5.4 g (30 mmol) of L-glucose, 30 ml of acetic anhydride, and 2.5 g of previously melted sodium acetate was heated at 950C for 2 hr. The mixture was decomposed with 12.0 g of ice water, stirred for 3 hr at 00C, and kept for 1 day at 250C. The precipitate was filtered and washed with 600 ml of water, dried on the filter, and washed with 60 ml of benzene/hexane, 1:1 (vol/vol). The product was recrystallized from ethanol (600 ml). The yield was 5.8 g (50%) having a melting point of 130-1310C. On thin-layer chromatography in cyclohexane/benzene/isopropylether/pyridine, 115:20:20:25 (vol/vol), the pentaacetate had RF 0.33. Pentaacetyl-D-glucopyranoside had the same RF value in this system: 2,3,4,6-Tetra-O-acetyl-a-L-glucopyranosyl Bromide. A solution of 3.9 g (10 mmol) of L-pentaacetylglucose in 20 ml of 45% (wt/vol) hydrogen bromide in acetic acid was kept at 4VC for 18 hr and subsequently at 250C for 4 hr. The mixture was then decomposed by the addition of 16 ml of ice water. The product was extracted with 300 ml of ether, and this solution was washed at 00C with three consecutive 400-ml portions of a 0.5 M potassium bicarbonate. The product was dried over anhydrous calcium chloride, the solvent was evaporated, and the residue was recrystallized from 20 ml of isopropyl ether. The yield was 1.95 g (47%) with a melting point of 88-890C. Thin-layer chromatography in the above described system gave an RF 0.47 for the bromide. The melting point and RF for the D-isomer were the same.
3-O-Benzoyl-N-palmitoylsphingosine (642 mg; 1 mmol) was heated in 30 ml of nitromethane and 30 ml of benzene until 15 ml of the benzene had been distilled off. The mixture was cooled and 505 mg (2 mmol) of mercuric cyanide and 411 mg (1 mmol) of 2,3,4,6-tetra-0-acetyl-a-L-glucopyranosyl bromide was added. The mixture was heated with stirring at 720C for 2 days. After cooling, 200 ml of ether was added and the solution was repeatedly washed with 0.5 M sodium bicarbonate until no mercuric ions were detected with a sodium sulfhydrate solution. The solvents were removed under reduced pressure and the residue was dissolved in 50 ml of methanol. Eight milliliters of 0.5 M sodium methylate in methanol was added; after 24 hr at room temperature, the mixture was neutralized with 0.23 ml of glacial acetic acid. To this solution were added 120 ml of chloroform and 36 ml of water. The suspension was shaken and the lower phase was washed once with the theoretical upper phase (10) and evaporated; the residue was dissolved in 400 ml of chloroform/methanol, 50:1 (vol/vol). The solution was chromatographed on a 50-g column of silic acid that was eluted with three chloroform/methanol mixtures: 1 liter of 50:1 (vol/vol), 600 ml of 30:1, and 300 ml of 9:1. The elution of glucocerebroside was monitored by thin-layer chromatography. The yield of L-glucosylceramide was 270 mg (39%). The product was crystallized from methanol (70 ml) and had a melting point of 182-1830C. The identity of the product was confirmed by elemental analysis. Calculated for C4oH-nNO8 (700.07): C, 68.63; H, 11.09; N, 2.00. Found: C, 69.28; H, 11.24; N, 2.04. Thin-layer chromatography in chloroform/methanol/water, 40:10:1 (vol/vol), gave an RF value for L-gluco-cerebroside of 0.55 (Fig. 1) . In a solvent system of chloroform/methanol/water, 65:25:4, the RF value was 0.8 ( Fig. 2) . The were identical to those of the L isomer. From this reaction 300 mg (56%) of N-palmitoylsphingosine was recovered. (Fig. 3) . Furthermore, the addition of the L isomer did not influence the hydrolysis of D-glucosylceramide when the glycolipids were incubated together in equimolar concentration, indicating that the analogue containing L-glucose does not interact with the active site on the enzyme.
Incubation of Tissue Extracts with D-and L-Glucosylceramides. When the glycolipids were incubated with whole mouse tissue extracts under conditions that allow expression of most lysosomal hydrolases, there was substantial ,B-glucosidase activity observed with the D isomer but no detectable hydrolysis of the L isomer (Table 1) . Because the normal mode of cleavage of glucosidase did not appear to be functioning with L-glucosylceramide, the possibility that the hydrolysis of the amide linkage resulted in the formation of glucosylsphingosine (psychosine) and free fatty acid was investigated. Examination cosylceramide standard. There was no indication of the formation of a labeled reaction product in the region of psychosine (Fig. 4) .
DISCUSSION
The stereochemistry of the D-and L-glucosylceramides is somewhat complex. Due to the additional asymmetric nature of sphingosine, the two cerebrosides are not pure enantiomorphs. The synthetic sphingosine with which the respective cerebrosides were prepared was, itself, a racemic mixture of D-and L-sphingosine. The conjugation to this racemic mixture of an additional optically active molecule (D-or L-glucose) results in an equimolar mixture of diastereoisomers. Consequently, the stereochemical relationship between the synthetic (Fig. 2) . The resolution obtained by this system can be judged from the decidedly slower migration of galactosylceramide than its 4-epimeric analogue glucosylceramide.
Because the refractoriness of L-glucosylceramide to enzymatic hydrolysis at both the glucosidic and amide linkages has been demonstrated in vitro, use of this glycolipid may be considered for a number of physiological and pathological investigations. The anticipated catabolic inertness of the L-hexosyl glycolipid in vsvo may enable one to mimic the storage of Dglucosylceramide that occurs in Gaucher disease with a high degree of fidelity. An investigation of the chronology of the appearance of cellular responses such as lysosomal hypertrophy induced by the accumulation of L-glucosylceramide should be particularly instructive. The influence of the form in which the glycolipid is administered (free, associated with lipoproteins, or incorporated into erythrocytes or leukocytes) may profoundly affect the uptake of the glycolipid. Furthermore, it will be possible to carry out examinations of the potential intercellular exchange of L-glucosylceramide between cells of the reticuloendothelial system with parenchymal cells (e.g., Kupffer cells and hepatocytes) and the possibility of the excretion of this lipid via the bile. It will also be of considerable interest to determine if L-glucosylceramide can enter anabolic pathways. The formation and disposition of such a "hybrid" synthetic natural product could provide considerable insight concerning the source, transport, and fate of complex sphingolipids.
In sum, the numerous investigative possibilities concerning the metabolism of L-glucosylceramide might be thought of as representing a reversal of natural processes. Metabolic disorders occur because mutant enzymes are no longer capable of interacting properly with their normal substrates. One can now attempt to alter physiological processes by presenting a "mutant" substrate to normal enzymes.
